Clinical trial
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney…
NCT00039429 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00039429 |
|---|---|
| Title | Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer |
| Official title | A Phase II Trial Evaluating Atrasentan In Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | atrasentan hydrochloride |
| Enrollment | 180 |
| Start date | Jul 14, 2003 |
| Primary completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 22, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: